drugset / Trial / NCT02268136

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

NCT02268136

Phase 1 Terminated 76 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The objective ot the present study is to obtain information about safety, tolerability and preliminary pharmacokinetics of BIII 890 CL after single intravenous administration of increasing doses in healthy male volunteers.

Timeline

Start
1999-04
Primary completion
1999-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Crobenetine Small molecule 0.5 mg Intravenous
Subject Crobenetine Small molecule 80 mg Intravenous

Indications

No indication recorded.